All Roads Lead to the miRNome: miRNAs Have a Central Role in the Molecular Pathophysiology of Psychiatric Disorders

Trends in Pharmacological Sciences

Volumn 37, Issue 12, 2016, Pages 1029-1044

  O'Connor, Richard M ^a   Gururajan, Anand ^b   Dinan, Timothy G ^b,c   Kenny, Paul J ^a   Cryan, John F ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 132; MICRORNA 137; RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENOME ANALYSIS; HUMAN; MENTAL DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MENTAL DISORDERS; PATHOPHYSIOLOGY;

ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MENTAL DISORDERS; MICRORNAS;

EID: 84995748218     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.10.004     Document Type: Review

References (125)

1. 1 Gururajan, A., et al. Molecular biomarkers of depression. Neurosci. Biobehav. Rev. 64 (2016), 101–133.
2. 2 Krol, J., et al. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11 (2010), 597–610.
3. 3 Boudreau, R.L., et al. Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron 81 (2014), 294–305.
4. 4 Lee, R.C., et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 (1993), 843–854.
5. 5 Wightman, B., et al. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75 (1993), 855–862.
6. 6 Marco, A., et al. Functional shifts in insect microRNA evolution. Genome Biol. Evol. 2 (2010), 686–696.
7. 7 Krichevsky, A.M., et al. A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 9 (2003), 1274–1281.
8. 8 Lagos-Quintana, M., et al. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12 (2002), 735–739.
9. 9 Podolska, A., et al. MicroRNA expression profiling of the porcine developing brain. PLoS One, 6, 2011, e14494.
10. 10 Brites, D., Fernandes, A., Neuroinflammation and depression: microglia activation, extracellular microvesicles and microRNA dysregulation. Front. Cell. Neurosci., 9, 2015, 476.
11. 11 Friedman, R.C., et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19 (2009), 92–105.
12. 12 Ebert, M.S., Sharp, P.A., Roles for microRNAs in conferring robustness to biological processes. Cell 149 (2012), 515–524.
13. 13 Vidigal, J.A., Ventura, A., The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol. 25 (2014), 137–147.
14. 14 Lee, R., et al. A short history of a short RNA. Cell 116 (2004), S89–S92.
15. 15 Issler, O., Chen, A., Determining the role of microRNAs in psychiatric disorders. Nat. Rev. Neurosci. 16 (2015), 201–212.
16. 16 Barbato, C., et al. Dicer expression and localization in post-mitotic neurons. Brain Res. 1175 (2007), 17–27.
17. 17 Kim, J., et al. A microRNA feedback circuit in midbrain dopamine neurons. Science 317 (2007), 1220–1224.
18. 18 Schaefer, A., et al. Cerebellar neurodegeneration in the absence of microRNAs. J. Exp. Med. 204 (2007), 1553–1558.
19. 19 Giraldez, A.J., et al. MicroRNAs regulate brain morphogenesis in zebrafish. Science 308 (2005), 833–838.
20. 20 Cheng, L.C., et al. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat. Neurosci. 12 (2009), 399–408.
21. 21 Szulwach, K.E., et al. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J. Cell Biol. 189 (2010), 127–141.
22. 22 Ashraf, S.I., et al. Synaptic protein synthesis associated with memory is regulated by the RISC pathway in Drosophila. Cell 124 (2006), 191–205.
23. 23 Lugli, G., et al. Expression of microRNAs and their precursors in synaptic fractions of adult mouse forebrain. J. Neurochem. 106 (2008), 650–661.
24. 24 Schratt, G.M., et al. A brain-specific microRNA regulates dendritic spine development. Nature 439 (2006), 283–289.
25. 25 Siegel, G., et al. A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat. Cell Biol. 11 (2009), 705–716.
26. 26 Ziats, M.N., Rennert, O.M., Identification of differentially expressed microRNAs across the developing human brain. Mol. Psychiatry 19 (2014), 848–852.
27. 27 Cristino, A.S., et al. Neurodevelopmental and neuropsychiatric disorders represent an interconnected molecular system. Mol. Psychiatry 19 (2014), 294–301.
28. 28 Arcila, M.L., et al. Novel primate miRNAs coevolved with ancient target genes in germinal zone-specific expression patterns. Neuron 81 (2014), 1255–1262.
29. 29 Li, J., et al. Evolution of an X-linked primate-specific micro RNA cluster. Mol. Biol. Evol. 27 (2010), 671–683.
30. 30 Koufaris, C., Human and primate-specific microRNAs in cancer: evolution, and significance in comparison with more distantly-related research models: the great potential of evolutionary young microRNA in cancer research. Bioessays 38 (2016), 286–294.
31. 31 Zhou, R., Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34 (2009), 1395–1405.
32. 32 Baudry, A., et al. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 329 (2010), 1537–1541.
33. 33 Launay, J.M., et al. Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16. Transl. Psychiatry, 1, 2011, e56.
34. 34 Issler, O., et al. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron 83 (2014), 344–360.
35. 35 Dias, C., et al. β-catenin mediates stress resilience through Dicer1/microRNA regulation. Nature 516 (2014), 51–55.
36. 36 Zhang, Y., et al. Dopamine receptor D2 and associated microRNAs are involved in stress susceptibility and resistance to escitalopram treatment. Int. J. Neuropsychopharmacol., 18, 2015, pyv025.
37. 37 Dwivedi, Y., et al. Chronic corticosterone-mediated dysregulation of microRNA network in prefrontal cortex of rats: relevance to depression pathophysiology. Transl. Psychiatry, 5, 2015, e682.
38. 38 Patricio, P., et al. Differential and converging molecular mechanisms of antidepressants’ action in the hippocampal dentate gyrus. Neuropsychopharmacology 40 (2015), 338–349.
39. 39 Li, Y., et al. miR-182 (microRNA-182) suppression in the hippocampus evokes antidepressant-like effects in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 65 (2016), 96–103.
40. 40 Fonken, L.K., et al. MicroRNA-155 deletion reduces anxiety- and depressive-like behaviors in mice. Psychoneuroendocrinology 63 (2016), 362–369.
41. 41 Rodgers, A.B., et al. Paternal stress exposure alters sperm microRNA content and reprograms offspring HPA stress axis regulation. J. Neurosci. 33 (2013), 9003–9012.
42. 42 Rodgers, A.B., et al. Transgenerational epigenetic programming via sperm microRNA recapitulates effects of paternal stress. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 13699–13704.
43. 43 Gapp, K., et al. Implication of sperm RNAs in transgenerational inheritance of the effects of early trauma in mice. Nat. Neurosci. 17 (2014), 667–669.
44. 44 Zarate, C. Jr., et al. Glutamatergic modulators: the future of treating mood disorders?. Harv. Rev. Psychiatry 18 (2010), 293–303.
45. 45 Zarate, C.A., et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry 161 (2004), 171–174.
46. 46 Greenhalgh, J., et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol. Assess. 9 (2005), 1–156.
47. 47 O'Connor, R.M., et al. microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. Int. J. Neuropsychopharmacol. 16 (2013), 1885–1892.
48. 48 Li, N., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69 (2011), 754–761.
49. 49 Liu, B.B., et al. 7-Chlorokynurenic acid (7-CTKA) produces rapid antidepressant-like effects: through regulating hippocampal microRNA expressions involved in TrkB–ERK/Akt signaling pathways in mice exposed to chronic unpredictable mild stress. Psychopharmacology 232 (2014), 541–550.
50. 50 Haramati, S., et al. MicroRNA as repressors of stress-induced anxiety: the case of amygdalar miR-34. J. Neurosci. 31 (2011), 14191–14203.
51. 51 Higuchi, F., Hippocampal MicroRNA-124 enhances chronic stress resilience in mice. J. Neurosci. 36 (2016), 7253–7267.
52. 52 Fan, H.M., et al. Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients. J. Psychiatr. Res. 59 (2014), 45–52.
53. 53 Jin, X.F., et al. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell. Mol. Neurobiol. 33 (2013), 601–613.
54. 54 Pulay, A.J., Rethelyi, J.M., Multimarker analysis suggests the involvement of BDNF signaling and microRNA biosynthesis in suicidal behavior. Am. J. Med. Genet. B Neuropsychiatr. Genet. 171 (2016), 763–776.
55. 55 Wingo, A.P., DICER1 and microRNA regulation in post-traumatic stress disorder with comorbid depression. Nat. Commu., 6, 2015, 10106.
56. 56 Maffioletti, E., et al. Peripheral whole blood microRNA alterations in major depression and bipolar disorder. J. Affect. Disord. 200 (2016), 250–258.
57. 57 Maheu, M., et al. MicroRNA regulation of central glial cell line-derived neurotrophic factor (GDNF) signalling in depression. Transl. Psychiatry, 5, 2015, e511.
58. 58 Belzeaux, R., et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl. Psychiatry, 2, 2012, e185.
59. 59 Garbett, K.A., et al. Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression. Biol. Psychiatry 77 (2014), 256–265.
60. 60 Schlaepfer, T.E., et al. Rapid effects of deep brain stimulation for treatment-resistant major depression. Biol. Psychiatry 73 (2013), 1204–1212.
61. 61 Soreq, L., et al. Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation–induced splicing changes that classify brain region transcriptomes. Front. Mol. Neurosci., 6, 2013, 10.
62. 62 Lopez, J.P., et al. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat. Med. 20 (2014), 764–768.
63. 63 Gururajan, A., MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c. Transl. Psychiatry, 6, 2016, e862.
64. 64 Smalheiser, N.R., et al. MicroRNA expression in rat brain exposed to repeated inescapable shock: differential alterations in learned helplessness vs. non-learned helplessness. Int. J. Neuropsychopharmacol. 14 (2011), 1315–1525.
65. 65 Smalheiser, N.R., et al. Enoxacin elevates microRNA levels in rat frontal cortex and prevents learned helplessness. Front. Psychiatry, 5, 2014, 6.
66. 66 Melo, S., et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 4394–4399.
67. 67 Shan, G., et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat. Biotechnol. 26 (2008), 933–940.
68. 68 Smalheiser, N.R., et al. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One, 7, 2012, e33201.
69. 69 Lehner, T., et al. Convergence of advances in genomics, team science, and repositories as drivers of progress in psychiatric genomics. Biol. Psychiatry 77 (2015), 6–14.
70. 70 Xu, Y., et al. A polymorphism in the microRNA-30e precursor associated with major depressive disorder risk and P300 waveform. J. Affect. Disord. 127 (2010), 332–336.
71. 71 Liang, Y., et al. Genetic variants in the promoters of let-7 family are associated with an increased risk of major depressive disorder. J. Affect. Disord. 183 (2015), 295–299.
72. 72 Jensen, K.P., et al. The effects of a MAP2K5 microRNA target site SNP on risk for anxiety and depressive disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 165B (2014), 175–183.
73. 73 Schmidt, U., et al. Therapeutic action of fluoxetine is associated with a reduction in prefrontal cortical miR–1971 expression levels in a mouse model of posttraumatic stress disorder. Front. Psychiatry, 4, 2013, 66.
74. 74 Song, H.T., et al. A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment. J. Psychiatr. Res. 54 (2014), 134–140.
75. 75 Beveridge, N.J., et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum. Mol. Genet. 17 (2008), 1156–1168.
76. 76 Perkins, D.O., et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol., 8, 2007, R27.
77. 77 Watanabe, Y., et al. Replication in a Japanese population that a MIR30E gene variation is associated with schizophrenia. Schizophr. Res. 150 (2013), 596–597.
78. 78 Xu, Y., et al. MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. Schizophr. Res. 119 (2010), 219–227.
79. 79 Schizophrenia Psychiatric Genome-Wide Association Study Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43 (2011), 969–976.
80. 80 Guella, I., et al. Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. J. Psychiatr. Res. 47 (2013), 1215–1221.
81. 81 Strazisar, M., et al. MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets. Mol. Psychiatry, 2014, 472–481.
82. 82 Cummings, E., et al. Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137. Neurosci. Lett. 532 (2013), 33–38.
83. 83 Green, M.J., et al. Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Mol. Psychiatry 18 (2013), 774–780.
84. 84 Lett, T.A., et al. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Mol. Psychiatry 18 (2013), 443–450.
85. 85 Liu, B., et al. The impact of MIR137 on dorsolateral prefrontal-hippocampal functional connectivity in healthy subjects. Neuropsychopharmacology, 2014, 2153–2160.
86. 86 Whalley, H.C., et al. Impact of a microRNA MIR137 susceptibility variant on brain function in people at high genetic risk of schizophrenia or bipolar disorder. Neuropsychopharmacology 37 (2012), 2720–2729.
87. 87 Kwon, E., et al. Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol. Psychiatry 18 (2013), 11–12.
88. 88 Kim, A.H., et al. Experimental validation of candidate schizophrenia gene ZNF804A as target for hsa-miR-137. Schizophr. Res. 141 (2012), 60–64.
89. 89 Olde Loohuis, N.F., et al. The schizophrenia risk gene MIR137 acts as a hippocampal gene network node orchestrating the expression of genes relevant to nervous system development and function. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016, 10.1016/j.pnpbp.2016.02.009 Published online February 27, 2016.
90. 90 Tamim, S., et al. Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells. PLoS One, 9, 2014, e85591.
91. 91 Valles, A., et al. MicroRNA-137 regulates a glucocorticoid receptor-dependent signalling network: implications for the etiology of schizophrenia. J. Psychiatry Neurosci., 39, 2014, 130269.
92. 92 Miller, B.H., et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 3125–3130.
93. 93 Wayman, G.A., et al. An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 9093–9098.
94. 94 Xiao, J., et al. MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway. Neuroscience, 268, 2014 128–113.
95. 95 Koob, G.F., Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56:Suppl. 1 (2009), 18–31.
96. 96 Heyer, M.P., Kenny, P.J., Corticostriatal microRNAs in addiction. Brain Res. 1628 (2015), 2–16.
97. 97 Jonkman, S., Kenny, P.J., Molecular, cellular, and structural mechanisms of cocaine addiction: a key role for microRNAs. Neuropsychopharmacology 38 (2013), 198–211.
98. 98 Hyman, S.E., et al. Neural mechanisms of addiction: the role of reward-related learning and memory. Ann. Rev. Neurosci. 29 (2006), 565–598.
99. 99 Koob, G.F., Volkow, N.D., Neurocircuitry of addiction. Neuropsychopharmacology 35 (2010), 217–238.
100. 100 Tsang, J., et al. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol. Cell 26 (2007), 753–767.
101. 101 Acar, M., et al. Enhancement of cellular memory by reducing stochastic transitions. Nature 435 (2005), 228–232.
102. 102 Gao, F.B., Posttranscriptional control of neuronal development by microRNA networks. Trends Neurosci. 31 (2008), 20–26.
103. 103 Hobert, O., Gene regulation by transcription factors and microRNAs. Science 319 (2008), 1785–1786.
104. 104 Schaefer, A., et al. Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction. J. Exp. Med. 207 (2010), 1843–1851.
105. 105 Chandrasekar, V., Dreyer, J.L., microRNAs miR-124, let-7d and miR-181a regulate cocaine-induced plasticity. Mol. Cell. Neurosci. 42 (2009), 350–362.
106. 106 Chandrasekar, V., Dreyer, J.L., Regulation of MiR-124, Let-7d, and MiR-181a in the accumbens affects the expression, extinction, and reinstatement of cocaine-induced conditioned place preference. Neuropsychopharmacology 36 (2011), 1149–1164.
107. 107 Eipper-Mains, J.E., et al. microRNA-Seq reveals cocaine-regulated expression of striatal microRNAs. RNA 17 (2011), 1529–1543.
108. 108 Hollander, J.A., et al. Striatal microRNA controls cocaine intake through CREB signalling. Nature 466 (2010), 197–202.
109. 109 Im, H.I., et al. MeCP2 controls BDNF expression and cocaine intake through homeostatic interactions with microRNA-212. Nat. Neurosci. 13 (2010), 1120–1127.
110. 110 Bali, P., Kenny, P.J., MicroRNAs and drug addiction. Front Genet., 4, 2013, 43.
111. 111 Quinn, R.K., et al. Distinct miRNA expression in dorsal striatal subregions is associated with risk for addiction in rats. Transl. Psychiatry, 5, 2015, e503.
112. 112 Pietrzykowski, A.Z., et al. Posttranscriptional regulation of BK channel splice variant stability by miR-9 underlies neuroadaptation to alcohol. Neuron 59 (2008), 274–287.
113. 113 Gorini, G., et al. Integration of miRNA and protein profiling reveals coordinated neuroadaptations in the alcohol-dependent mouse brain. PLoS One, 8, 2013, e82565.
114. 114 Bahi, A., Dreyer, J.L., Striatal modulation of BDNF expression using microRNA124a-expressing lentiviral vectors impairs ethanol-induced conditioned-place preference and voluntary alcohol consumption. Eur. J. Neurosci. 38 (2013), 2328–2337.
115. 115 Novo-Veleiro, I., et al. A genetic variant in the microRNA-146a gene is associated with susceptibility to alcohol use disorders. Eur. Psychiatry 29 (2014), 288–292.
116. 116 O'Connor, R.M., et al. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression. Mol. Psychiatry 17 (2012), 359–376.
117. 117 O'Brien, F.E., et al. Interactions between antidepressants and P-glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings. Br. J. Pharmacol. 165 (2012), 289–312.
118. 118 O'Brien, F.E., et al. P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents. Neuropsychopharmacology 38 (2013), 2209–2219.
119. 119 Gomez, D., et al. Intranasal treatment of neurodegenerative diseases and stroke. Front. Biosci. 4 (2012), 74–89.
120. 120 Hache, M., et al. Intrathecal injections in children with spinal muscular atrophy: Nusinersen Clinical Trial Experience. J. Child. Neurol. 31 (2016), 899–906.
121. 121 Merritt, W.M., et al. The dicey role of Dicer: implications for RNAi therapy. Cancer Res. 70 (2010), 2571–2574.
122. 122 Lanford, R.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327 (2010), 198–201.
123. 123 van der Ree, M.H., et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res. 111 (2014), 53–59.
124. 124 Fischer, A., Cavazzana-Calvo, M., Gene therapy of inherited diseases. Lancet 371 (2008), 2044–2047.
125. 125 Lehmann, S.M., et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat. Neurosci. 15 (2012), 827–835.